Lupus Hub

How frequently do you schedule follow-up visits for patients with lupus to monitor disease activity? A. Every 3–6 months B. Every 7–12 months C. As needed, depending on symptoms and severity D. I don’t have a set follow-up schedule HCPs, please let us know your thoughts! #Lupus…

New publication 📝 The 2025 ACR guidelines published in @ACRheum recommend universal use of hydroxychloroquine therapy in all patients with SLE, and early introduction of conventional and/or biologic therapies. Learn more about the guidelines here: loom.ly/OoYfwZM…

Did you know you can filter content on the #Lupus Hub website depending on your specific interests – whether that is by lupus type, therapeutics, trials, or congresses? 👉 loom.ly/otsujjM #MedEd

Catch up on the latest developments in real-world studies and management strategies in #lupus from #EULAR2025, with live social media coverage from the Lupus Hub. 👉 loom.ly/GQmrYEY #MedEd #MedicalCongress #RheumTwitter

Catch up on the latest developments in phase III trials in #lupus from #EULAR2025, with live social media coverage from the Lupus Hub. 👉 loom.ly/qSHSayY #MedEd #MedicalCongress #RheumTwitter

Catch up on the latest developments in early-phase trials in #lupus from #EULAR2025, with live social media coverage from the Lupus Hub. 👉 loom.ly/U4JpjvE #MedEd #MedicalCongress #RheumTwitter

🚨 NEWS 🚨 @US_FDA approves belimumab 200 mg/mL autoinjector for the treatment of patients aged ≥5 years with active #LupusNephritis, who are receiving standard therapy. Read more: loom.ly/afj0EuI #lupus #MedEd #MedNews #RheumTwitter

CONGRESS | #EULAR2025 | PLENARY SESSION Antonis Fanouriakis, National and Kapodistrian University of Athens, highlighted recent advances in #lupus nephritis during his plenary session on #SLE. · Higher initial GC dose was associated with better renal outcomes but also increased…

CONGRESS | #EULAR2025 | PLENARY SESSION Antonis Fanouriakis, National and Kapodistrian University of Athens, gave a talk about recent advances in #SLE including pathogenesis, treatment strategy and major clinical trials in 2024-2025. · Genetic burden of SLE may lead to…

CONGRESS | #EULAR2025 | POSTER Amit Saxena, @nyulangone, presented 48-week results from the phase 2 SLEek study of ABBV-599 (elsubrutinib+upadacitinib) and upadacitinib monotherapy in pts with #SLE. · Comparable improvements in BILAG domains across the combination and…

CONGRESS | #EULAR2025 | POSTER Edward M @edvital, @UniversityLeeds, presented consensus-based guidance for GC tapering in pts with #SLE. · A consensus-based decision-tree model was developed to guide GC tapering approaches. · 100% of respondents stated that IS or biologics…

CONGRESS | #EULAR2025 | POSTER Ioannis Parodis, @IoannisParodis, @KarolinskaInst, provided 48-week results from phase 3 PHOENYCS GO study on the impact of dapirolizumab pegol (DZP) on fatigue in pts with #SLE. Greater improvements with DZP vs PBO · FACIT-F score: 50.55% vs 35.5%…

CONGRESS | #EULAR2025 | POSTER Eric Morand, @EricFMorand, @MonashUni, presented a post hoc analysis of PAISLEY #SLE phase 2 trial of deucravacitinib in achieving a GC taper to ≤7.5 mg/day and avoidance of BILAG-2004 flares. · Majority of pts were able to achieve GC taper at…

CONGRESS | #EULAR2025 | POSTER Joseph F Merola, @UT_Dallas, summarised results from PAISLEY CLE phase 2 trial of deucravacitinib in pts with cutaneous #lupus. · Significantly greater improvements in CLASI-A rates with deucravacitinib (-50.0%) vs PBO (-28.4%; p=0.00385) at Week…

CONGRESS | #EULAR2025 | POSTER Ioannis Parodis, @IoannisParodis, @KarolinskaInst, presented a post hoc analysis of five phase 3 trials of belimumab in pts with #SLE in achieving remission and low disease activity. At Week 52: · Higher rates of DORIS-no-GC (18.% vs 12.8%) and…

CONGRESS | #EULAR2025 | POSTER Edward M. Vital @edvital, @UniversityLeeds, presented results from the phase III PHOENYCS GO trial (NCT04294667) of dapirolizumab pegol in patients with #SLE (N = 315). The primary endpoint was met; 49.5% of patients receiving dapirolizumab pegol +…

CONGRESS | #EULAR2025 | POSTER Zahi Touma, @ZahiTouma, @UofT, @UofT_DoM, presented data from the LASER study of anifrolumab in pts with #SLE. · Significantly less organ damage accumulation with anifrolumab vs real-world SoC (HR:0.401). · Less organ damage over 10 years with…

CONGRESS | #EULAR2025 | POSTER Mariele Gatto, University of Turin, presented a post hoc summary of five phase 3 trials of belimumab in pts with #SLE. Versus conventional IS, · Higher rate of SRI-4 response · Lower rate of flares · Reduction in mean cumulative GC dose · Lower…

CONGRESS | #EULAR2025 | PRESENTATION Eric Morand, @MonashUni, presented findings from Cohort B of the phase II WILLOW trial (NCT05162586) evaluating enpatoran in patients with active #SLE (N=354). At Week 24, all doses of enpatoran showed improved BICLA response rates vs placebo,…

CONGRESS | #EULAR2025 | PRESENTATION Jane E. Salmon, @WeillCornell, discussed results from the phase II IMPACT trial (NCT03152058) evaluating certolizumab in high-risk pregnancies with anti-phospholipid syndrome and lupus anticoagulant (N=51). The primary adverse pregnancy…